ClinicalTrials.gg
RecruitingNCT06541535DRINKUpdated Nov 17, 2026

Fluid Administration in Ketoacidosis (DRINK)

A Phase 4 interventional study of Fluid resuscitation with isotonic saline only and Fluid resuscitation with Ringer Lactate in Diabetic Keto-acidosis, sponsored by Centre Hospitalier Universitaire de Nice. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Centre Hospitalier Universitaire de Nice · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Updated Nov 10, 2026Primary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Acidosis with a site in France — 4 open to participants now, 4 under way, none of them phase 3. Acidosis · France.

Started
2025
with 1 other
Phase 4
2 of 12
1 open now
Registered
10th of 12
by date
Lead sponsor
1 of 12
Centre Hospitalier Universitaire de Nice

Among the 12 studies in Acidosis with a site in France, this one is one of 2 that started in 2025, is one of 2 in phase 4, and was the 10th registered.

Acidosis

111 studies on the registry are indexed under Acidosis; 19 are open to participants now.

Browse Acidosis studies →

Open to participants now

4 of the 12 studies in Acidosis with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 17 Acidosis studies recruiting now, 13 (76%) set no upper age limit and 2 (12%) stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Acidosis with a site in France, or all of them as a file.
02

Study summary

Management of severe diabetic ketoacidosis is based on insulin therapy, correction of metabolic disorders and fluid resuscitation. Current recommendations recommend the first-line use of isotonic saline, whose composition is unbalanced, rich in chloride and sodium compared with plasma. Administration of large volumes of isotonic saline is associated with a risk of hyperchloremic metabolic acidosis and acute renal failure. Balanced solutions (e.g. Ringer Lactate) are solutions with a more balanced electrolyte composition close to that of plasma. They could therefore enable diabetic ketoacidosis to be resolved more quickly than isotonic saline, due to a lower risk of hyperchloremic acidosis. Preliminary data suggest a potential benefit of balanced solutions for fluid resuscitation of patients with severe diabetic ketoacidosis in terms of resolution of diabetic ketoacidosis, but no randomized controlled double-blind study to date has compared balanced solution vs. isotonic saline in this context.

03

Conditions studied

  • Diabetic Keto-acidosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admission to emergency department or direct admission to ICU
  • Diagnosis of severe diabetic ketoacidosis requiring all the following criteria:
  • Blood or capillary glucose > 11 mmol/L
  • Ketonemia or ketonuria > 0
  • Venous or arterial pH \< 7.30 or venous or arterial bicarbonate \< 15 mmol/L
  • Volume of fluid administered before inclusion \<1L

Exclusion criteria

Exclusion Criteria:

  • Patients \<18 years
  • Pregnant women
  • Patients under protection
  • Patients with a decision to withdraw life-sustaining therapy
  • to isotonic saline or Ringer Lactate
  • Non-affiliation to social security
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Active comparator
    Isotonic saline

    Drug: Fluid resuscitation with isotonic saline only

  • Experimental
    Ringer Lactate

    Drug: Fluid resuscitation with Ringer Lactate

Interventions

  • DrugFluid resuscitation with isotonic saline only

    Isotonic saline only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines: * During the first hour of treatment: * In the event of systolic arterial hypotension (SAP\<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour. * In the absence of systolic arterial hypotension (SAP\>90mmHg): administration of 1L over 1 hour. * Between 60 minutes and 8 hours of treatment : * 1L over 2 hours, repeated once, then 1L over 4 hours * Adjust fluid resuscitation according to clinical tolerance * After the first 8 hours: * 1L over 4h then 1L over 6h * Clinical re-evaluation according to standard of care in participating centers

  • DrugFluid resuscitation with Ringer Lactate

    Ringer Lactate only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines: * During the first hour of treatment: * In the event of systolic arterial hypotension (SAP\<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour. * In the absence of systolic arterial hypotension (SAP\>90mmHg): administration of 1L over 1 hour. * Between 60 minutes and 8 hours of treatment : * 1L over 2 hours, repeated once, then 1L over 4 hours * Adjust fluid resuscitation according to clinical tolerance * After the first 8 hours: * 1L over 4h then 1L over 6h * Clinical re-evaluation according to standard of care in participating centers

06

What researchers measure

Primary outcomes

  1. Resolution of diabetic ketoacidosis

    Compare fluid resuscitaiton with Ringer Lactate to isotonic saline on the resolution of diabetic ketoacidosis at 24 hours from admission to Intensive Care Unit (ICU) in patients with severe diabetic ketoacidosis. Resolution of ketoacidosis allowing discharge from ICU, defined as the proportion of patients with the following three criteria at 24 hours from ICU admission : 1. capillary or blood glucose \< 11 mmol/L 2. ketonemia \< 0.6 mmol/l 3. venous or arterial pH ≥ 7,30 or venous or arterial bicarbonate ≥ 18 mmol/L

    Time frame: at 24 hours

Secondary outcomes

  1. Speed of resolution of metabolic disorders

    Compare fluid resuscitation with Ringer Lactate and isotonic saline solution on the speed of resolution of metabolic disorders in patients admitted to ICU for severe diabetic ketoacidosis. Proportion of patients and number of hours ("Resolution free hours") within 48 hours of ICU admission with the following three criteria: 1. capillary or blood glucose \< 11 mmol/L 2. ketonemia \< 0.6 mmol/l 3. venous or arterial pH ≥ 7,30 or venous or arterial bicarbonate ≥ 18 mmol/L

    Time frame: at 48 hours

  2. Time of resolution of metabolic disorders

    Compare fluid resuscitation with Ringer Lactate and isotonic saline solution on the speed of resolution of metabolic disorders in patients admitted to ICU for severe diabetic ketoacidosis. Time (in hours) from ICU admission to obtain one of the following three criteria: 1. capillary or blood glucose \< 11 mmol/L 2. ketonemia \< 0.6 mmol/l 3. venous or arterial pH ≥ 7,30 or venous or arterial bicarbonate ≥ 18 mmol/L

    Time frame: at 48 hours

  3. Assess the metabolic tolerance of Ringer Lactate compared to isotonic saline solution

    Assess the metabolic tolerance of Ringer Lactate compared to isotonic saline solution in patients admitted to ICU for severe diabetic ketoacidosis. Occurrence of serious metabolic disorders during ICU stay, defined as : 1. Kalemia \< 3 mmol/L 2. Natremia \> 145 mmol/L 3. Chloremia \> 110 mmol/L 4. Phosphoremia \< 0.70 mmol/L 5. Blood glucose \< 3.8 mmol/L (i.e. 0.80 g/L) 6. Persistent ketonemia 24 hours after ICU admission 2. Nature and volume (in liters) of fluid administered before inclusion and during the study period in each group 3. Protocol compliance (expressed as % of volume administered in each group)

    Time frame: through the end of study average 24 months

  4. Assess the impact of Ringer lactate compared with isotonic saline on renal, neurological and cardiac complications

    To assess the impact of Ringer lactate compared with isotonic saline on renal, neurological and cardiac complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis. Occurrence of adverse events during ICU stay, defined as : 1. Neurological disorders (Glasgow score) 2. Acute renal failure (KDIGO classification) 3. Cardiac disorders (supraventricular and ventricular rhythm disorders, acute coronary syndrome) 2. ICU and hospital length of stay 3. ICU mortality and Day-28 mortality

    Time frame: at 28 days

  5. Assess the impact of Ringer lactate compared with isotonic saline on cardiac complications

    To assess the impact of Ringer lactate compared with isotonic saline on cardiac complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis. Occurrence of adverse events during ICU stay, defined as : * Cardiac disorders (supraventricular and ventricular rhythm disorders, acute coronary syndrome) * ICU and hospital length of stay * ICU mortality and Day-28 mortality

    Time frame: at 28 days

  6. Assess the impact of Ringer lactate compared with isotonic saline on renal complications

    To assess the impact of Ringer lactate compared with isotonic saline on renal, complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis. Measure acute renal failure with KDIGO classification. The Kidney Disease: Improving Global Outcomes (KDIGO) classification system stratifies acute kidney injury (AKI) into levels of severity, determined by changes in serum creatinine (SCr) / estimated creatinine clearance (eCCl), as well as changes in urine output. The strata of severity of AKI can be reached by meeting the criteria for changes in SCr / eCCl or changes in urine output. There are three levels of severity, with level 1 being the least severe and level 3 the most severe. No cut-off for the study

    Time frame: at 28 days

  7. Assess the impact of Ringer lactate compared with isotonic saline on neurological complications

    To assess the impact of Ringer lactate compared with isotonic saline on neurological complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis. Measure Neurological disorders with Glasgow score. The Glasgow Coma Scale (GCS) is used to objectively describe the extent of impaired consciousness in all types of patients. The scale rates patients on three aspects of reactivity: eye opening, motor responses and verbal responses. It ranges from 3 (coma) to 15 (no disturbance of consciousness). No cut-off for the study.

    Time frame: at 28 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2024
First posted
Aug 7, 2024
StartActual
Nov 26, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Jul 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionResolution of diabetic ketoacidosis: how it is measured was reworded
Nov 10, 2026
Secondary outcomes
Revised in 2 updates
What changed on Nov 10, 2026
  • DescriptionSpeed of resolution of metabolic disorders: how it is measured was reworded
  • DescriptionTime of resolution of metabolic disorders: how it is measured was reworded
What changed on Nov 17, 2026
  • DescriptionAssess the metabolic tolerance of Ringer Lactate compared to isotonic saline solution: how it is measured was reworded
across 2 updates, Nov 10, 2026 – Nov 17, 2026
Show all 2 updates
  1. Nov 17, 2026
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionAssess the metabolic tolerance of Ringer Lactate compared to isotonic saline solution: how it is measured was reworded
  2. Nov 10, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionResolution of diabetic ketoacidosis: how it is measured was reworded
    Secondary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionSpeed of resolution of metabolic disorders: how it is measured was reworded
    • DescriptionTime of resolution of metabolic disorders: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06541535
Responsible party
Sponsor
First posted
Aug 7, 2024
Start date
Nov 26, 2025
Primary completion
Dec 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Mathieu JOZWIAK, MD PhD
Contact
jozwiak.m@chu-nice.fr
+33492035510

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion